New Treatment From Shockwave Medical For Clogged Arteries Gets CMS Pass-Through Payment
Starting 1 July, Medicare beneficiaries with a certain type of cardiovascular disease will be able to receive an innovative treatment covered under their government plans.
You may also be interested in...
The US Medicare agency increased payment for peripheral Intravascular Lithotripsy (IVL) procedures in a final rule. The increase is good news for Shockwave Medical, whose proprietary IVL treatment uses a novel approach to treating calcified arteries.
Citing the pandemic, the US Centers for Medicare & Medicaid Services (CMS) discounted 2020 data in reviewing renewals for New Technology Add-On Payment (NTAP) status and granted extensions through 30 September to 13 NTAP products.
Shockwave Medical received a FDA premarket approval for its C2 coronary intravascular lithotripsy-based calcification remedy and announced its 2020 results, in line with expectations.